KRAS and neoplasm: Second, there are notable differences in the frequency of KRAS mutation (range 48–13%) or MSI-H status (range 4–20%) and pCR rate (range 7–43%) between studies, which may reflect the inhomogeneity of molecular techniques across laboratories and over time, as well as different clinical procedures for tumor response assessment or different treatment protocols.